



Jim Doyle
Governor

Helene Nelson
Secretary

State of Wisconsin

Department of Health and Family Services

Telephone: 608-266-8922
FAX: 608-266-1096
TTY: 608-261-7798
dhfs.wisconsin.gov

**OPEN MEETING NOTICE
MEDICAID PHARMACY
PRIOR AUTHORIZATION ADVISORY COMMITTEE**

Wednesday, August 16, 2006

8:30 a.m. – 4:30 p.m.

**Wisconsin State Office Building
1 W. Wilson Street, Room 751
Madison, Wisconsin 53701**

AGENDA

- 8:30 a.m. – 8:45 a.m. **I. Opening Remarks/Introductions**
- II. Approval of Minutes**
- III. Conflict of Interest Policy**
- IV. Decisions of the Secretary**
- 8:45 a.m. – 10:15 a.m. **V. Public Comment**
- 10:15 a.m. – 10:30 a.m. **VI. Break**
- 10:30 a.m. – 12:00 p.m. **VII. Public Comment cont.**
- 12:00 p.m. – 12:15 p.m. **VIII. Break/Lunch**
- 12:15 p.m. – 2:15 p.m. **IX. Discussion of Manufacturer-Specific Supplemental Rebate Amounts (Closed Session)***
- 2:15 p.m. – 2:30 p.m. **X. Break**
- 2:30 p.m. – 4:30 p.m. **XI. Therapeutic Class Reviews, Committee Discussion and Response to Proposal (Open Session)**

Drug Classes for Review:*

- ACE Inhibitors (High blood pressure)
- Platelet Aggregation Inhibitors (Prevention of blood clots)
- Atopic Dermatitis (Eczema)
- Antifungals, Topical (Skin fungal infections)
- Antifungals, Oral (Nail and other fungal infections)
- Antivirals (Flu/Herpes)
- Cephalosporins/Related Antibiotics (Antibiotics for infection)
- Fluoroquinolones (Antibiotics for infection)
- Macrolides/Ketolides (Antibiotics for infection)
- Ophthalmics, Antibiotics (Infection of the eyes)
- Ophthalmics, Allergic Conjunctivitis (Eye Allergies)
- Ophthalmics, Glaucoma Agents (Treatment of eye condition that can cause sight loss)
- Leukotriene Modifiers (Asthma)
- Bronchodilators, Beta Agonists (Asthma)
- Bronchodilators, Anticholinergic (Emphysema)
- Glucocorticoids, Inhaled (Asthma)
- Intranasal Rhinitis (Allergies)
- Antiemetics (Prevention of nausea and vomiting)
- Hypoglycemics, Insulins (Diabetes)
- Bone Resorp. Suppress./Related Agents (Osteoporosis)
- Cytokine and CAM Antagonists (Rheumatoid arthritis and psoriasis)
- NSAIDs (Pain Control)
- Androgenic Agents (Male Sex Hormones)
- Alzheimer's Agents (Alzheimer's Disease)
- Antiparkinson's Agents (Parkinson's Disease)
- Antidepressants, SSRIs (Depression)
- Stimulants and Related Agents (Attention deficit disorder and attention deficit hyperactivity disorder)
- **Analgesics, Narcotic – Ultram ER**
- **Hypoglycemics, TZDs – Avandaryl**
- **Proton Pump Inhibitors – Zegerid**

* Intended for consideration in closed session pursuant to s. 19.85(1)(e), Wis. Stats.

Contact Person: Carrie Gray (608) 266-3901, E-mail – GRAYCL@dhfs.state.wi.us

Accessibility: The meeting is accessible for people with mobility impairments. Handicapped parking is available in the parking lot in back of the building. An accessible entrance is found in back of the building nearest the handicapped parking or in front of the building, using the side entrance. People needing special accommodations to attend or participate in the meeting should notify the contact person at least five working days prior to the meeting.

cc: State Editor, Milwaukee Journal Sentinel
State Editor, The Capital Times
State Editor, Wisconsin State Journal

Posted - State Capitol Building
Posted - 1 W. Wilson St., Madison

Medicaid Prior Authorization Advisory Committee Meeting

Public Testimony Guidelines:

ATTENTION: In the past speakers were limited to 5 minutes of testimony. Because of the number of drug classes up for review, speakers may be limited to less than 5 minutes. The time limitation will be announced at the start of the public testimony.

1. Speakers are required to sign up with the Division of Health Care Financing (DHCF) prior to the meeting. Please contact Carrie Gray via e-mail at GRAYCL@dhfs.state.wi.us or by phone at (608) 266-3901 to reserve a time slot.
2. Speakers must complete the Wisconsin Medicaid Pharmacy Prior Authorization Committee Presenter/Witness Disclosure form prior to providing testimony. This form will be e-mailed to you with your approximate speaking time.
3. Speakers must sign in when arriving at the meeting and return completed Presenter/Witness Disclosure forms to DHCF staff prior to speaking. Forms will also be available at the registration table.
4. Speakers must submit a written copy of their testimony to Carrie Gray, either prior to or at the meeting. Testimony copies may be submitted via e-mail at GRAYCL@dhfs.state.wi.us or mailed to the Division of Health Care Financing, Attn: Carrie Gray, 1 W. Wilson Street, Room 350, Madison, WI 53702.
5. Should all slots for spoken testimony become filled, parties are invited to submit written testimony for review and consideration by the Committee. Written testimony should be submitted to Carrie Gray via e-mail at GRAYCL@dhfs.state.wi.us or mailed to the Division of Health Care Financing, Attn: Carrie Gray, 1 W. Wilson Street, Room 350, Madison, WI 53702.
6. Multiple speakers per company or organization will be permitted.
7. Speakers will be required to state name, address, organization represented, and the drug name and class applicable to their testimony.
8. Because of the number of drug classes up for review, speakers may be limited to less than 5 minutes. The time limitation will be announced at the start of the public testimony.
9. Speakers will NOT be permitted to use audio/visual equipment during their presentation.
10. Speakers will NOT be permitted to provide handouts to the Prior Authorization Committee members prior to or during the meeting.
11. Prior Authorization Committee members will not ask questions or respond to speakers during the public testimony.
12. Speakers are welcome to remain for Committee deliberations. Committee members may elect to address questions to speakers who gave testimony earlier.